4/25
04:46 pm
asnd
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
Low
Report
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
4/24
08:30 am
asnd
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
Low
Report
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
4/22
01:22 pm
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $116.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $116.00 price target on the stock.
4/18
10:23 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $173.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $173.00 price target on the stock.
4/16
09:15 am
asnd
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr. [Yahoo! Finance]
Low
Report
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr. [Yahoo! Finance]
4/16
09:00 am
asnd
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
Low
Report
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
4/8
04:15 am
asnd
Advancements and Opportunities in the Achondroplasia Market: A Comprehensive Analysis and Forecast to 2032 [Yahoo! Finance]
Low
Report
Advancements and Opportunities in the Achondroplasia Market: A Comprehensive Analysis and Forecast to 2032 [Yahoo! Finance]
4/2
11:04 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $165.00 to $167.00. They now have an "overweight" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $165.00 to $167.00. They now have an "overweight" rating on the stock.
4/1
09:01 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $173.00 price target on the stock.
High
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $173.00 price target on the stock.
3/22
09:57 am
asnd
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last? [Yahoo! Finance]
Low
Report
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last? [Yahoo! Finance]
3/22
05:40 am
asnd
Ascendis Pharma A/S (ASND) Rose on Positive Trial Results [Yahoo! Finance]
Medium
Report
Ascendis Pharma A/S (ASND) Rose on Positive Trial Results [Yahoo! Finance]
3/7
09:14 pm
asnd
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China [Yahoo! Finance]
Low
Report
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China [Yahoo! Finance]
3/7
09:00 pm
asnd
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
Low
Report
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
3/4
08:30 am
asnd
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
Medium
Report
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
2/15
02:01 pm
asnd
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]
Low
Report
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]
2/15
11:00 am
asnd
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? [Yahoo! Finance]
2/10
07:25 am
asnd
US$172 - That's What Analysts Think Ascendis Pharma A/S (NASDAQ:ASND) Is Worth After These Results [Yahoo! Finance]
Low
Report
US$172 - That's What Analysts Think Ascendis Pharma A/S (NASDAQ:ASND) Is Worth After These Results [Yahoo! Finance]
2/8
11:43 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Citigroup Inc. from $146.00 to $182.00. They now have a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Citigroup Inc. from $146.00 to $182.00. They now have a "buy" rating on the stock.
2/8
10:18 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/8
08:32 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Wedbush from $207.00 to $225.00. They now have an "outperform" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Wedbush from $207.00 to $225.00. They now have an "outperform" rating on the stock.
2/7
04:16 pm
asnd
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]
Low
Report
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]
2/7
04:01 pm
asnd
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
Low
Report
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
2/7
09:50 am
asnd
3 Top-Ranked Small-Cap Growth Mutual Funds Worth Betting On [Yahoo! Finance]
Low
Report
3 Top-Ranked Small-Cap Growth Mutual Funds Worth Betting On [Yahoo! Finance]
2/7
08:30 am
asnd
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Low
Report
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/6
10:37 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Cantor Fitzgerald from $152.00 to $173.00. They now have an "overweight" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Cantor Fitzgerald from $152.00 to $173.00. They now have an "overweight" rating on the stock.